Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cartellieri

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Blood Cancer Journal|August 13, 2016
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blastsM Cartellieri, A Feldmann, S Koristka, et al.
Leukemia|January 18, 2013
Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cellsC Arndt, M von Bonin, M Cartellieri, et al.
Blood Cancer Journal|September 19, 2015
Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blastsR Aliperta, M Cartellieri, A Feldmann, et al.
Leukemia|March 19, 2011
Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cellsS Stamova, M Cartellieri, A Feldmann, et al.
Leukemia|August 21, 2013
Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting systemC Arndt, A Feldmann, M von Bonin, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Blood Cancer Journal|August 13, 2016
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blastsM Cartellieri, A Feldmann, S Koristka, et al.
Leukemia|January 18, 2013
Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cellsC Arndt, M von Bonin, M Cartellieri, et al.
Blood Cancer Journal|September 19, 2015
Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blastsR Aliperta, M Cartellieri, A Feldmann, et al.
Leukemia|March 19, 2011
Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cellsS Stamova, M Cartellieri, A Feldmann, et al.
Leukemia|August 21, 2013
Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting systemC Arndt, A Feldmann, M von Bonin, et al.
Pageof 3